Product Description
Personalized Neoantigen Cancer Vaccine for Treating Patients With Advanced Malignant Tumor (Sourced from: https://clinicaltrials.gov/ct2/history/NCT03662815?V_3=View)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sir Run Run Shaw Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Pancreatic Cancer|Esophageal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05307835 |
INEO-P-006 | P1 |
Active, not recruiting |
Esophageal Cancer |
2026-06-30 |
50% |
2025-12-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT04810910 |
INEO-P-005 | P1 |
Unknown status |
Pancreatic Cancer |
2025-03-30 |
88% |
2025-04-01 |
|
NCT03662815 |
INEO-P-002 | P1 |
Unknown status |
Pancreatic Cancer |
2021-05-20 |
12% |
2023-11-03 |
Primary Endpoints|Treatments|Trial Status |
NCT03645148 |
INEO-P-001 | P1 |
Completed |
Pancreatic Cancer |
2020-11-01 |
61% |
2021-11-17 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |